Inventiva (IVA) to Release Earnings on Wednesday

Inventiva (NASDAQ:IVA) will likely be issuing its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect Inventiva to post earnings of ($0.18) per share and revenue of $8.6730 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Inventiva Stock Up 1.3%

Shares of IVA opened at $6.16 on Wednesday. Inventiva has a 1 year low of $2.70 and a 1 year high of $7.98. The business’s 50 day simple moving average is $6.24 and its 200-day simple moving average is $5.36.

Hedge Funds Weigh In On Inventiva

Institutional investors have recently bought and sold shares of the company. Creative Planning purchased a new position in shares of Inventiva in the 2nd quarter valued at about $32,000. Virtu Financial LLC purchased a new stake in shares of Inventiva during the fourth quarter worth approximately $60,000. XTX Topco Ltd purchased a new position in Inventiva during the 4th quarter worth $84,000. NewEdge Advisors LLC purchased a new position in Inventiva during the third quarter worth about $116,000. Finally, Cerity Partners LLC acquired a new stake in Inventiva in the fourth quarter valued at about $93,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on IVA shares. Leerink Partners started coverage on shares of Inventiva in a research report on Monday, January 12th. They issued an “outperform” rating and a $12.00 price target on the stock. HC Wainwright set a $24.00 price objective on shares of Inventiva and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. Barclays initiated coverage on shares of Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 target price on the stock. Finally, UBS Group initiated coverage on shares of Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $17.00.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.